The biopharmaceutical industry has witnessed significant advancements in upstream bioprocessing over the years, but downstream bioprocessing (DSP) often lagged, creating bottlenecks that hampered overall efficiency. Recent innovations, however, are transforming the DSP landscape, offering promising
The biopharmaceutical industry is on the cusp of a revolutionary transformation that promises to redefine its future trajectory. While Biopharma 4.0 brought about significant advancements in digitization and smart manufacturing, its successor, Biopharma 5.0, aims to integrate human creativity,
Bioprocessing, with its roots in the early days of microbial fermentation, now stands as a fundamental pillar in the realm of modern biotechnology. This sophisticated field merges biological and engineering principles to harness the power of living organisms in producing a vast array of valuable
Verdot, a leader in downstream purification solutions for the biopharmaceutical industry, is making headlines with its ambitious plans to expand manufacturing capacity by 150%. This development is taking place in Riom, France — a location with historical significance for the company. The extensive
The global biopharmaceutical contract manufacturing market is anticipated to experience significant growth from 2024 to 2032. This market's expansion is driven by continuous technological innovations, increased research and development (R&D) investments, and strategic collaborations among key
Biomanufacturing, the engineering of biological materials for products like pharmaceuticals, is poised for radical change. Historically reliant on specialized labor and manual processes, the sector is now at the cusp of a technological revolution powered by artificial intelligence (AI) and machine
